Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via ...

The State Department issued a waiver for lifesaving aid, but HIV clinics remain shut and uncertainty lingers over the future ...

The Trump administration's aid freeze affects HIV treatment access. Find out how organizations are coping with the directive.

Patients and health care advocates said the abrupt decision to halt U.S. funding for a lifesaving H.I.V. program led to widespread confusion. The backtracking didn’t help.

A recent flurry of executive orders and surprise actions by the Trump administration have roiled WHO, the CDC and the international public health community.